Hyperimmune Globulins Market - Size, Share, Industry Trends, and Forecasts (2023 - 2031)

By Dosage Form :

By dosage form the hyperimmune globulins market is categorized into powder form and liquid form. In 2022, the liquid form segment accounted for the highest market share in the overall hyperimmune globulins market, and it is expected to hold the highest CAGR over the forecast period. Analysis of market trends concludes that the increasing prevalence of chronic bacterial and viral infections, along with the growing availability of immunotherapy options, is driving the demand for liquid dosage forms of the globulins. Liquid medications are not only cost-effective but also easy to administer to the body. Unlike powdered drugs that require further dilution, hyperimmune globulin drugs are available as ready-to-inject liquid solutions. Moreover, new product launches and government approvals are expected to drive the segment globally. Instance, On May 3, 2023, Kamada Ltd. a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, announced the U.S. Food and Drug Administration (FDA) approval for the manufacturing of CYTOGAM® (Cytomegalovirus Immune Globulin Intravenous [Human]) (CMV-IGIV) at the Company's facility in Beit Kama, Israel. CYTOGAM is a sterile liquid antibody solution indicated for the prophylaxis of cytomegalovirus disease (CMV) associated with the transplantation of the kidney, lung, liver, pancreas, and heart, and is the sole FDA-approved immunoglobulin (IgG) product for this indication.

By Product Type :

The product type is categorized into immunoglobulins for hepatitis B, immunoglobulins for botulism, immunoglobulins for rabies, immunoglobulins for tetanus, Rho (D) immunoglobulins, and others. In 2022, the Rho (D) immunoglobulins segment accounted for the highest hyperimmune globulins market share. Rho(D) immune globulin (RhIG) is a medication used to manage and treat Rh-negative pregnancies and immune thrombocytopenic purpura (ITP), which is a blood disorder characterized by a low number of platelets that are essential for blood clotting. Rho(D) immune globulin is also used to prevent the formation of antibodies after a person with Rh-negative blood receives a transfusion with Rh-positive blood. ABO / Rh D type and antibody screen is performed early in pregnancy.

Moreover, the immunoglobulins for the hepatitis B segment are expected to hold the highest CAGR over the forecast period. The demand for hepatitis B segment is increasing due to the rising incidences and concerns about viral diseases. For instance, according to the report by the World Health Organization in July 2023, an estimated 58 million people have chronic hepatitis C virus infection, with about 1.5 million new infections occurring per year globally. Analysis of market trends concludes that new product launches in the hyperimmune globulins market are expected to boost the market in the future. For instance, on June 1, 2021 – Grifols, a leading global producer of plasma-derived medicines and provider of a variety of postexposure prophylaxis and IgG products for patients, launched HyperHEP B, a new formulation of hepatitis B immune globulin [human] for hepatitis B postexposure prophylaxis. Thus, the growing prevalence of viral disease is expected to provide lucrative opportunities for segment growth across the globe.

By Application :

The application segment of the hyperimmune globulins market is categorized into infections, immunodeficiency, and autoimmune disorders. In 2022, the infections segment accounted for the highest market share of 39.25% in the hyperimmune globulins market and it is expected to hold the highest CAGR over the forecast period. Despite the introduction of antibiotics and vaccines, plasma hyperimmunoglobulin therapy from whole blood donation plays a major role. Hyperimmune globulin treatment involves the transfer of high-titer antibodies from immunized human donors to provide immediate protection against specific diseases. This treatment either reduces the risk or severity of the infection. Antibody preparations derived from immunized human donors are commonly used to prevent and treat diseases such as rabies, hepatitis A and B viruses, varicella-zoster virus, pneumonia caused by respiratory syncytial virus, Clostridium tetani, cytomegalovirus infection during solid organ transplantation and Clostridium botulinum infection. Additionally, increasing incidences and prevalence of bacterial and viral infections worldwide are driving the segment across the globe. Examination of market trends concludes that the rise in the prevalence of outbreaks of infectious diseases is expected to drive the segment globally. For instance, according to the report published by WHO in February 2022, in 2020, 15 (29.4%) of the countries and territories in the Region of the Americas had at least one Zika virus surveillance report available.

By Region :

The regional segment includes North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America.

In 2022, North America accounted for the highest market share at 34.20% valued at USD 604.32 million in 2022 and USD 642.77 million in 2023, it is expected to reach USD 1,087.76 million in 2031. In North America, the U.S. accounted for a major market share of 64.25% in the year 2022. The market in North America is experiencing profilation due to the presence of major industry players in the region, advanced healthcare facilities and services, increased awareness about plasma donations, and the establishment of more plasma collection centers throughout the region. According to the data published by the Federal Deposit Insurance Corporation on February 7, 2022, between 2012 and 2021, the number of plasma centers in the United States increased from 400 to over 1000, and plasma collected in the U.S. more than doubled. Plasma centers in the United States collect around two-thirds of the global plasma supply. Examination of market trends concludes that the growing pharmaceutical research and development is substantially driving the hyperimmune globulins market growth. For instance, according to the report by the National Center for Science and Engineering Statistics in September 2023, in financial year (FY) 2022, the 42 federally funded research and development centers (FFRDCs) in the United States spent USD 26.5 billion on research and development (R&D). This was a 6.4% increase from the previous year. The hyperimmune globulins market analysis concluded that the rise in plasma collection centers and the rising pharmaceutical research and development spending across the region are propelling the market in North America.

Furthermore, the Asia Pacific region is expected to witness significant growth over the forecast period, growing at a CAGR of 7.3% during 2023-2031. The large patient population, significant expansion of the pharmaceutical sector and healthcare sector across the region is expected to increase the demand for hyperimmune globulins across the region. Analysis of hyperimmune globulins market trends concludes that the growth in the pharmaceutical industry post-COVID-19 in the Asia Pacific region is also expected to propel the hyperimmune globulins market. For instance, according to the report by the Indian Brand Equity Foundation in August 2023, the market size of the Indian pharmaceuticals industry is expected to reach USD 65 billion by 2024, and USD 130 billion by 2030, and the largest number of FDA-approved plants outside the US is in India. All these above-mentioned facors are collectively driving the demand for the market in the Asia Pacific region and creating lucrative growth opportunities for the hyperimmune globulins market in the Asia Pacific region.